Immune Response in Patients with Recurrent or Metastatic Non-Small Cell Lung Cancer

What we are studying

The purpose of this research study is to compare the effects (good and bad) of pembrolizumab given every three weeks with or without low dose carboplatin and paclitaxel. The drug pembrolizumab is in a class of medications called monoclonal antibodies. It works by helping your immune system to slow or stop the growth of cancer cells. Pembrolizumab had been approved for the treatment of melanomas and is being studied for the treatment of patients with Non-Small Cell Lung Cancer . Carboplatin and paclitaxel are chemotherapy drugs approved by the US Food and Drug Administration (FDA) for treatment of your disease. The goal of this study is to determine if carboplatin and paclitaxel can improve the anti-tumor activity of pembrolizumab.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Confirmed non small cell lung cancer

What is involved

  • Post treatment biopsy
  • Blood and urine collections
  • Study questionnaires



Contact Information

Study Coordinator
Sharon Averill, RN

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.